StreetInsider.com News Articles

Entheon Announces Execution of Business Combination Agreement with Nutravisor

Mon, 19 Jan 2026 17:28:00 -0500

Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into a definitive business combination agreement (the "Business Combination Agreement") with Nutravisor Inc. ("Nutravisor"), dated January 19, 2026, pursuant to which the parties have agreed to complete a business combination involving a "three-cornered" amalgamation of Nutravisor with a wholly-owned subsidiary of Entheon ("Subco") that will have the effect of Entheon acquiring all of the issued and outstanding common shares (the "Nutravisor Shares") and other securities of Nutravisor in exchange for securities

Entheon Announces Execution of Business Combination Agreement with Nutravisor

Mon, 19 Jan 2026 17:28:00 -0500

Entheon Announces Letter of Intent with Nutravisor Inc.

Mon, 22 Dec 2025 09:30:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into a binding Letter of Intent (the "LOI") dated December 18, 2025, with Nutravisor Inc. ("Nutravisor") whereby Entheon will acquire all of the issued and outstanding common shares of Nutravisor (the "Proposed Transaction"). Upon completion of the Proposed Transaction, the combined entity will continue the business of Nutravisor (the "Resulting Issuer").

"Nutravisor is thrilled to move forward with this transaction. The successful completion of Proposed Transaction is expected to help

Entheon Announces Letter of Intent with Nutravisor Inc.

Mon, 22 Dec 2025 09:30:00 -0500

"Nutravisor is thrilled to move forward with this transaction. The successful completion of Proposed Transaction is expected to help

Entheon Announces Change of Directors

Fri, 04 Apr 2025 20:20:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - April 4, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces the appointment of Harrison Newlands to the Company's Board of Directors, effective April 3, 2025.

Harrison Newlands has a diverse understanding of start-ups and capital markets, having invested, advised, and helped co-found dozens of mid-cap companies spanning close to a decade of experience in the industry. He started his career working on Bay Street as a Research Associate at MacNicol and Associates, thereafter he jumped into the fast growing cannabis industry, and was one of the co-founders of

Entheon Announces Change of Directors

Fri, 04 Apr 2025 20:20:00 -0500

Entheon Issues Incentive Stock Options

Mon, 31 Mar 2025 16:30:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that the Company has granted options to purchase up to an aggregate 40,000 common shares in the Company (the "Options") to certain directors of the Company. The Options are exercisable at $0.145 per share for a period of two years from the date of grant. The Options have been granted under and are governed by the terms of the Company's incentive stock option plan approved by the Company's shareholders at its annual general meeting held on December

Entheon Issues Incentive Stock Options

Mon, 31 Mar 2025 16:30:00 -0500

Entheon Announces Termination of Mentis AI Agreement

Fri, 14 Mar 2025 17:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - March 14, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that, further to its news release dated January 24, 2025, 1000141080 Ontario Ltd. ("Mentis AI") has terminated the letter of intent ("LOI") dated January 23, 2025 which set out the terms whereby Entheon would acquire all of the issued and outstanding common shares in the capital of Mentis AI.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,
Timothy Ko, CEO,

Entheon Announces Termination of Mentis AI Agreement

Fri, 14 Mar 2025 17:00:00 -0500

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,
Timothy Ko, CEO,

Entheon Announces Agreement to Acquire Mentis AI

Fri, 24 Jan 2025 10:34:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - January 24, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into a binding letter of intent ("LOI") dated January 23, 2025 with 1000141080 Ontario Ltd. ("Mentis AI"), pursuant to which Entheon will acquire all of the issued and outstanding common shares in the capital of Mentis AI (the "Transaction").

Mentis AI (mentisai.ca) is a privately held research and development company focused on the acquisition and development of AI technologies for the purposes of helping those suffering from a variety

Entheon Announces Agreement to Acquire Mentis AI

Fri, 24 Jan 2025 10:34:00 -0500

Mentis AI (mentisai.ca) is a privately held research and development company focused on the acquisition and development of AI technologies for the purposes of helping those suffering from a variety